Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial

Johann S. de Bono, Nicole Concin, David S. Hong, Fiona C. Thistlethwaite, Jean Pascal Machiels, Hendrik Tobias Arkenau, Ruth Plummer, Robert Hugh Jones, Dorte Nielsen, Kristian Windfeld, Srinivas Ghatta, Brian Slomovitz, James F. Spicer, Jeffrey Yachnin, Joo Ern Ang, Paul Morten Mau-Sørensen, Martin David Forster, Dearbhaile Collins, Emma Dean, Reshma A. RangwalaUlrik Lassen

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Tisotumab vedotin is a first-in-human antibody–drug conjugate directed against tissue factor, which is expressed across multiple solid tumour types and is associated with poor clinical outcomes. We aimed to establish the safety, tolerability, pharmacokinetic profile, and antitumour activity of tisotumab vedotin in a mixed population of patients with locally advanced or metastatic (or both) solid tumours known to express tissue factor. Methods: InnovaTV 201 is a phase 1–2, open-label, dose-escalation and dose-expansion study done at 21 centres in the USA and Europe. Patients (aged ≥18 years) had relapsed, advanced, or metastatic cancer of the ovary, cervix, endometrium, bladder, prostate, oesophagus, squamous cell carcinoma of the head and neck or non-small-cell lung cancer; an Eastern Cooperative Oncology Group performance status of 0–1; and had relapsed after or were not eligible to receive the available standard of care. No specific tissue factor expression level was required for inclusion. In the dose-escalation phase, patients were treated with tisotumab vedotin between 0·3 and 2·2 mg/kg intravenously once every 3 weeks in a traditional 3 + 3 design. In the dose-expansion phase, patients were treated at the recommended phase 2 dose. The primary endpoint was the incidence of adverse events, including serious adverse events, infusion-related, treatment-related and those of grade 3 or worse, and study drug-related adverse events, analysed in all patients who received at least one dose of tisotumab vedotin (full analysis population). This trial is registered with ClinicalTrials.gov, number NCT02001623, and is closed to new participants with follow-up ongoing. Findings: Between Dec 9, 2013, and May 18, 2015, 27 eligible patients were enrolled to the dose-escalation phase. Dose-limiting toxicities, including grade 3 type 2 diabetes mellitus, mucositis, and neutropenic fever, were seen at the 2·2 mg/kg dose; therefore, 2·0 mg/kg of tisotumab vedotin intravenously once every 3 weeks was established as the recommended phase 2 dose. Between Oct 8, 2015, and April 26, 2018, 147 eligible patients were enrolled to the dose-expansion phase. The most common (in ≥20% of patients) treatment-emergent adverse events of any grade were epistaxis (102 [69%] of 147 patients), fatigue (82 [56%]), nausea (77 [52%]), alopecia (64 [44%]), conjunctivitis (63 [43%]), decreased appetite (53 [36%]), constipation (52 [35%]), diarrhoea (44 [30%]), vomiting (42 [29%]), peripheral neuropathy (33 [22%]), dry eye (32 [22%]), and abdominal pain (30 [20%]). The most common adverse events of grade 3 or worse were fatigue (14 [10%] of 147 patients), anaemia (eight [5%]), abdominal pain (six [4%]), hypokalaemia (six [4%]), conjunctivitis (five [3%]), hyponatraemia (five [3%]), and vomiting (five [3%]). 67 (46%) of 147 patients had a treatment-emergent serious adverse event. 39 (27%) of 147 patients had a treatment-emergent serious adverse event related to the study drug. Infusion-related reactions occurred in 17 (12%) of 147 patients. Across tumour types, the confirmed proportion of patients who achieved an objective response was 15·6% (95% CI 10·2–22·5; 23 of 147 patients). There were nine deaths across all study phases (three in the dose-escalation phase and six in the dose-expansion phase); only one case of pneumonia in the dose-expansion phase was considered possibly related to study treatment. Interpretations: Tisotumab vedotin has a manageable safety profile with encouraging preliminary antitumour activity across multiple tumour types in heavily pretreated patients. Continued evaluation of tisotumab vedotin is warranted in solid tumours. Funding: Genmab A/S.

Original languageEnglish (US)
Pages (from-to)383-393
Number of pages11
JournalThe Lancet Oncology
Volume20
Issue number3
DOIs
StatePublished - Mar 1 2019

Fingerprint

Neoplasms
Thromboplastin
Conjunctivitis
Abdominal Pain
Vomiting
Fatigue
Therapeutics
Safety
Mucositis
Epistaxis
Hypokalemia
Hyponatremia
Alopecia
Peripheral Nervous System Diseases
Appetite
Constipation
Standard of Care
Endometrium
Drug-Related Side Effects and Adverse Reactions
Non-Small Cell Lung Carcinoma

ASJC Scopus subject areas

  • Oncology

Cite this

de Bono, J. S., Concin, N., Hong, D. S., Thistlethwaite, F. C., Machiels, J. P., Arkenau, H. T., ... Lassen, U. (2019). Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial. The Lancet Oncology, 20(3), 383-393. https://doi.org/10.1016/S1470-2045(18)30859-3

Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201) : a first-in-human, multicentre, phase 1–2 trial. / de Bono, Johann S.; Concin, Nicole; Hong, David S.; Thistlethwaite, Fiona C.; Machiels, Jean Pascal; Arkenau, Hendrik Tobias; Plummer, Ruth; Jones, Robert Hugh; Nielsen, Dorte; Windfeld, Kristian; Ghatta, Srinivas; Slomovitz, Brian; Spicer, James F.; Yachnin, Jeffrey; Ang, Joo Ern; Mau-Sørensen, Paul Morten; Forster, Martin David; Collins, Dearbhaile; Dean, Emma; Rangwala, Reshma A.; Lassen, Ulrik.

In: The Lancet Oncology, Vol. 20, No. 3, 01.03.2019, p. 383-393.

Research output: Contribution to journalArticle

de Bono, JS, Concin, N, Hong, DS, Thistlethwaite, FC, Machiels, JP, Arkenau, HT, Plummer, R, Jones, RH, Nielsen, D, Windfeld, K, Ghatta, S, Slomovitz, B, Spicer, JF, Yachnin, J, Ang, JE, Mau-Sørensen, PM, Forster, MD, Collins, D, Dean, E, Rangwala, RA & Lassen, U 2019, 'Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial', The Lancet Oncology, vol. 20, no. 3, pp. 383-393. https://doi.org/10.1016/S1470-2045(18)30859-3
de Bono, Johann S. ; Concin, Nicole ; Hong, David S. ; Thistlethwaite, Fiona C. ; Machiels, Jean Pascal ; Arkenau, Hendrik Tobias ; Plummer, Ruth ; Jones, Robert Hugh ; Nielsen, Dorte ; Windfeld, Kristian ; Ghatta, Srinivas ; Slomovitz, Brian ; Spicer, James F. ; Yachnin, Jeffrey ; Ang, Joo Ern ; Mau-Sørensen, Paul Morten ; Forster, Martin David ; Collins, Dearbhaile ; Dean, Emma ; Rangwala, Reshma A. ; Lassen, Ulrik. / Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201) : a first-in-human, multicentre, phase 1–2 trial. In: The Lancet Oncology. 2019 ; Vol. 20, No. 3. pp. 383-393.
@article{c74c69ed2ce3485f8bf0ea03bb0fcf0b,
title = "Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial",
abstract = "Background: Tisotumab vedotin is a first-in-human antibody–drug conjugate directed against tissue factor, which is expressed across multiple solid tumour types and is associated with poor clinical outcomes. We aimed to establish the safety, tolerability, pharmacokinetic profile, and antitumour activity of tisotumab vedotin in a mixed population of patients with locally advanced or metastatic (or both) solid tumours known to express tissue factor. Methods: InnovaTV 201 is a phase 1–2, open-label, dose-escalation and dose-expansion study done at 21 centres in the USA and Europe. Patients (aged ≥18 years) had relapsed, advanced, or metastatic cancer of the ovary, cervix, endometrium, bladder, prostate, oesophagus, squamous cell carcinoma of the head and neck or non-small-cell lung cancer; an Eastern Cooperative Oncology Group performance status of 0–1; and had relapsed after or were not eligible to receive the available standard of care. No specific tissue factor expression level was required for inclusion. In the dose-escalation phase, patients were treated with tisotumab vedotin between 0·3 and 2·2 mg/kg intravenously once every 3 weeks in a traditional 3 + 3 design. In the dose-expansion phase, patients were treated at the recommended phase 2 dose. The primary endpoint was the incidence of adverse events, including serious adverse events, infusion-related, treatment-related and those of grade 3 or worse, and study drug-related adverse events, analysed in all patients who received at least one dose of tisotumab vedotin (full analysis population). This trial is registered with ClinicalTrials.gov, number NCT02001623, and is closed to new participants with follow-up ongoing. Findings: Between Dec 9, 2013, and May 18, 2015, 27 eligible patients were enrolled to the dose-escalation phase. Dose-limiting toxicities, including grade 3 type 2 diabetes mellitus, mucositis, and neutropenic fever, were seen at the 2·2 mg/kg dose; therefore, 2·0 mg/kg of tisotumab vedotin intravenously once every 3 weeks was established as the recommended phase 2 dose. Between Oct 8, 2015, and April 26, 2018, 147 eligible patients were enrolled to the dose-expansion phase. The most common (in ≥20{\%} of patients) treatment-emergent adverse events of any grade were epistaxis (102 [69{\%}] of 147 patients), fatigue (82 [56{\%}]), nausea (77 [52{\%}]), alopecia (64 [44{\%}]), conjunctivitis (63 [43{\%}]), decreased appetite (53 [36{\%}]), constipation (52 [35{\%}]), diarrhoea (44 [30{\%}]), vomiting (42 [29{\%}]), peripheral neuropathy (33 [22{\%}]), dry eye (32 [22{\%}]), and abdominal pain (30 [20{\%}]). The most common adverse events of grade 3 or worse were fatigue (14 [10{\%}] of 147 patients), anaemia (eight [5{\%}]), abdominal pain (six [4{\%}]), hypokalaemia (six [4{\%}]), conjunctivitis (five [3{\%}]), hyponatraemia (five [3{\%}]), and vomiting (five [3{\%}]). 67 (46{\%}) of 147 patients had a treatment-emergent serious adverse event. 39 (27{\%}) of 147 patients had a treatment-emergent serious adverse event related to the study drug. Infusion-related reactions occurred in 17 (12{\%}) of 147 patients. Across tumour types, the confirmed proportion of patients who achieved an objective response was 15·6{\%} (95{\%} CI 10·2–22·5; 23 of 147 patients). There were nine deaths across all study phases (three in the dose-escalation phase and six in the dose-expansion phase); only one case of pneumonia in the dose-expansion phase was considered possibly related to study treatment. Interpretations: Tisotumab vedotin has a manageable safety profile with encouraging preliminary antitumour activity across multiple tumour types in heavily pretreated patients. Continued evaluation of tisotumab vedotin is warranted in solid tumours. Funding: Genmab A/S.",
author = "{de Bono}, {Johann S.} and Nicole Concin and Hong, {David S.} and Thistlethwaite, {Fiona C.} and Machiels, {Jean Pascal} and Arkenau, {Hendrik Tobias} and Ruth Plummer and Jones, {Robert Hugh} and Dorte Nielsen and Kristian Windfeld and Srinivas Ghatta and Brian Slomovitz and Spicer, {James F.} and Jeffrey Yachnin and Ang, {Joo Ern} and Mau-S{\o}rensen, {Paul Morten} and Forster, {Martin David} and Dearbhaile Collins and Emma Dean and Rangwala, {Reshma A.} and Ulrik Lassen",
year = "2019",
month = "3",
day = "1",
doi = "10.1016/S1470-2045(18)30859-3",
language = "English (US)",
volume = "20",
pages = "383--393",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "3",

}

TY - JOUR

T1 - Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201)

T2 - a first-in-human, multicentre, phase 1–2 trial

AU - de Bono, Johann S.

AU - Concin, Nicole

AU - Hong, David S.

AU - Thistlethwaite, Fiona C.

AU - Machiels, Jean Pascal

AU - Arkenau, Hendrik Tobias

AU - Plummer, Ruth

AU - Jones, Robert Hugh

AU - Nielsen, Dorte

AU - Windfeld, Kristian

AU - Ghatta, Srinivas

AU - Slomovitz, Brian

AU - Spicer, James F.

AU - Yachnin, Jeffrey

AU - Ang, Joo Ern

AU - Mau-Sørensen, Paul Morten

AU - Forster, Martin David

AU - Collins, Dearbhaile

AU - Dean, Emma

AU - Rangwala, Reshma A.

AU - Lassen, Ulrik

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Background: Tisotumab vedotin is a first-in-human antibody–drug conjugate directed against tissue factor, which is expressed across multiple solid tumour types and is associated with poor clinical outcomes. We aimed to establish the safety, tolerability, pharmacokinetic profile, and antitumour activity of tisotumab vedotin in a mixed population of patients with locally advanced or metastatic (or both) solid tumours known to express tissue factor. Methods: InnovaTV 201 is a phase 1–2, open-label, dose-escalation and dose-expansion study done at 21 centres in the USA and Europe. Patients (aged ≥18 years) had relapsed, advanced, or metastatic cancer of the ovary, cervix, endometrium, bladder, prostate, oesophagus, squamous cell carcinoma of the head and neck or non-small-cell lung cancer; an Eastern Cooperative Oncology Group performance status of 0–1; and had relapsed after or were not eligible to receive the available standard of care. No specific tissue factor expression level was required for inclusion. In the dose-escalation phase, patients were treated with tisotumab vedotin between 0·3 and 2·2 mg/kg intravenously once every 3 weeks in a traditional 3 + 3 design. In the dose-expansion phase, patients were treated at the recommended phase 2 dose. The primary endpoint was the incidence of adverse events, including serious adverse events, infusion-related, treatment-related and those of grade 3 or worse, and study drug-related adverse events, analysed in all patients who received at least one dose of tisotumab vedotin (full analysis population). This trial is registered with ClinicalTrials.gov, number NCT02001623, and is closed to new participants with follow-up ongoing. Findings: Between Dec 9, 2013, and May 18, 2015, 27 eligible patients were enrolled to the dose-escalation phase. Dose-limiting toxicities, including grade 3 type 2 diabetes mellitus, mucositis, and neutropenic fever, were seen at the 2·2 mg/kg dose; therefore, 2·0 mg/kg of tisotumab vedotin intravenously once every 3 weeks was established as the recommended phase 2 dose. Between Oct 8, 2015, and April 26, 2018, 147 eligible patients were enrolled to the dose-expansion phase. The most common (in ≥20% of patients) treatment-emergent adverse events of any grade were epistaxis (102 [69%] of 147 patients), fatigue (82 [56%]), nausea (77 [52%]), alopecia (64 [44%]), conjunctivitis (63 [43%]), decreased appetite (53 [36%]), constipation (52 [35%]), diarrhoea (44 [30%]), vomiting (42 [29%]), peripheral neuropathy (33 [22%]), dry eye (32 [22%]), and abdominal pain (30 [20%]). The most common adverse events of grade 3 or worse were fatigue (14 [10%] of 147 patients), anaemia (eight [5%]), abdominal pain (six [4%]), hypokalaemia (six [4%]), conjunctivitis (five [3%]), hyponatraemia (five [3%]), and vomiting (five [3%]). 67 (46%) of 147 patients had a treatment-emergent serious adverse event. 39 (27%) of 147 patients had a treatment-emergent serious adverse event related to the study drug. Infusion-related reactions occurred in 17 (12%) of 147 patients. Across tumour types, the confirmed proportion of patients who achieved an objective response was 15·6% (95% CI 10·2–22·5; 23 of 147 patients). There were nine deaths across all study phases (three in the dose-escalation phase and six in the dose-expansion phase); only one case of pneumonia in the dose-expansion phase was considered possibly related to study treatment. Interpretations: Tisotumab vedotin has a manageable safety profile with encouraging preliminary antitumour activity across multiple tumour types in heavily pretreated patients. Continued evaluation of tisotumab vedotin is warranted in solid tumours. Funding: Genmab A/S.

AB - Background: Tisotumab vedotin is a first-in-human antibody–drug conjugate directed against tissue factor, which is expressed across multiple solid tumour types and is associated with poor clinical outcomes. We aimed to establish the safety, tolerability, pharmacokinetic profile, and antitumour activity of tisotumab vedotin in a mixed population of patients with locally advanced or metastatic (or both) solid tumours known to express tissue factor. Methods: InnovaTV 201 is a phase 1–2, open-label, dose-escalation and dose-expansion study done at 21 centres in the USA and Europe. Patients (aged ≥18 years) had relapsed, advanced, or metastatic cancer of the ovary, cervix, endometrium, bladder, prostate, oesophagus, squamous cell carcinoma of the head and neck or non-small-cell lung cancer; an Eastern Cooperative Oncology Group performance status of 0–1; and had relapsed after or were not eligible to receive the available standard of care. No specific tissue factor expression level was required for inclusion. In the dose-escalation phase, patients were treated with tisotumab vedotin between 0·3 and 2·2 mg/kg intravenously once every 3 weeks in a traditional 3 + 3 design. In the dose-expansion phase, patients were treated at the recommended phase 2 dose. The primary endpoint was the incidence of adverse events, including serious adverse events, infusion-related, treatment-related and those of grade 3 or worse, and study drug-related adverse events, analysed in all patients who received at least one dose of tisotumab vedotin (full analysis population). This trial is registered with ClinicalTrials.gov, number NCT02001623, and is closed to new participants with follow-up ongoing. Findings: Between Dec 9, 2013, and May 18, 2015, 27 eligible patients were enrolled to the dose-escalation phase. Dose-limiting toxicities, including grade 3 type 2 diabetes mellitus, mucositis, and neutropenic fever, were seen at the 2·2 mg/kg dose; therefore, 2·0 mg/kg of tisotumab vedotin intravenously once every 3 weeks was established as the recommended phase 2 dose. Between Oct 8, 2015, and April 26, 2018, 147 eligible patients were enrolled to the dose-expansion phase. The most common (in ≥20% of patients) treatment-emergent adverse events of any grade were epistaxis (102 [69%] of 147 patients), fatigue (82 [56%]), nausea (77 [52%]), alopecia (64 [44%]), conjunctivitis (63 [43%]), decreased appetite (53 [36%]), constipation (52 [35%]), diarrhoea (44 [30%]), vomiting (42 [29%]), peripheral neuropathy (33 [22%]), dry eye (32 [22%]), and abdominal pain (30 [20%]). The most common adverse events of grade 3 or worse were fatigue (14 [10%] of 147 patients), anaemia (eight [5%]), abdominal pain (six [4%]), hypokalaemia (six [4%]), conjunctivitis (five [3%]), hyponatraemia (five [3%]), and vomiting (five [3%]). 67 (46%) of 147 patients had a treatment-emergent serious adverse event. 39 (27%) of 147 patients had a treatment-emergent serious adverse event related to the study drug. Infusion-related reactions occurred in 17 (12%) of 147 patients. Across tumour types, the confirmed proportion of patients who achieved an objective response was 15·6% (95% CI 10·2–22·5; 23 of 147 patients). There were nine deaths across all study phases (three in the dose-escalation phase and six in the dose-expansion phase); only one case of pneumonia in the dose-expansion phase was considered possibly related to study treatment. Interpretations: Tisotumab vedotin has a manageable safety profile with encouraging preliminary antitumour activity across multiple tumour types in heavily pretreated patients. Continued evaluation of tisotumab vedotin is warranted in solid tumours. Funding: Genmab A/S.

UR - http://www.scopus.com/inward/record.url?scp=85062188343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062188343&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(18)30859-3

DO - 10.1016/S1470-2045(18)30859-3

M3 - Article

C2 - 30745090

AN - SCOPUS:85062188343

VL - 20

SP - 383

EP - 393

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 3

ER -